



SOOTHING SCENTS: ADVANCING INTEGRATIVE ONCOLOGY WITH AROMATHERAPY FOR IMPROVED CHEMOTHERAPY SYMPTOM MANAGEMENT

Aqsa Ghaffar, BA¹, Myla Strawderman, MS², Tanzy Love, PhD², Madeline Forster, MS³, Arlette Chavez, MD⁴, Denise Rokitka, MD⁵, Julie Ryan Wolf, PHD, MPH⁶ ¹School of Medicine & Dentistry, ²Biostatistics and Computational Biology, ³Surgery, ⁴Wilmot Cancer Institute, ⁶Dermatology, University of Rochester Medical Center, Rochester, NY, USA ⁵Roswell Park Cancer Institute, Buffalo, NY, USA Research Supported by: Wilmot Cancer Institute Pilot Award (OP346036) & UR CTSA (UL1 TR002001)

INTRODUCTION


- Cancer patients endure symptoms not only from the disease, but also its treatment
- Adverse effects include nausea, vomiting, pain, fatigue, and anxiety, markedly reducing quality of life and presenting challenges to treatment adherence¹
- Aromatherapy is a non-invasive, low-risk, and low-cost intervention
- Preliminary evidence have shown essential oils ginger, lavender, orange, and lemon are effective in symptom management, however further clinical studies are necessary to establish its therapeutic benefits²⁻⁵





	%	90% Confidence Interval
Overall Retention Rate	86.8%	[79.5, 92.2]
Overall Aromatherapy Compliance Rate	88.6%	[81.0, 93.9]
Overall Aromatherapy Recommendation Rate	82.5%	[72.7, 89.9]

Change in Mean Composite Symptom Severity Score (CSSS)



OBJECTIVE

utonomic functions and emotions.⁶

Aromatherapy is proposed to exert its effects through stimulation of olfactory receptor cells, transmitting impulses to the limbic system, which is central to

To conduct a blinded, randomized clinical trial to evaluate the feasibility and benefit of four aromatherapy scents (ginger, lavender, and orange, and jojoba) in management of chemotherapy-related symptoms.

REFERENCES


Thiagarajan M, Chan CM, Fuang HG, Beng TS, Atiliyana MA, Yahaya NA. Symptom Prevalence and Related Distress in Cancer Patients Undergoing Chemotherapy. Asian Pac J Cancer Prev. 2016;17(1):171-6. doi: 10.7314/apjcp.2016.17.1.171. PMID: 26838205.
Nascimento JC, Gonçalves VSS, Souza BRS, Nascimento LC, Carvalho BMR, Ziegelmann PK, Goes TC, Guimarães AG. New approaches to the effectiveness of inhalation aromatherapy in controlling painful conditions: A systematic review with meta-analysis. Complement Ther Clin Pract. 2022 Nov;49:101628. doi: 10.1016/ j.ctcp.2022.101628. Epub 2022 Jun 28. PMID: 35792408.
Blackburn L, Achor S, Allen B, Bauchmire N, Dunnington D, Klisovic RB, Naber SJ, Roblee K, Samczak A, Tomlinson-Pinkham K, Chipps E. The Effect of Aromatherapy on Insomnia and Other Common Symptoms Among Patients With Acute Leukemia. Oncology nursing forum. 2017;44(4):E185-E93. doi: 10.10188/17.0NF.E185-E193. Windowski order control of the second research of the second rese acm.2010.0862. PubMed PMÍD: 22784340.⁻
5. Nakayama M, Okizaki A, Takahashi K. A Randomized Controlled Trial for the Effectiveness of Aromatherapy in Decreasing Salivary Gland Damage following Radioactive Iodine Therapy for Differentiated Thyroid Cancer. BioMed research international. 2016;2016:9509810. doi: 10.1155/2016/9509810. PubMed PMID: 28042578; PubMed Central PMCID: PMC5155074.
6. Fung TKH, Lau BWM, Ngai SPC, Tsang HWH. Therapeutic Effect and Mechanisms of Essential Oils in Mood Disorders: Interaction between the Nervous and Respiratory Systems. Int J Mol Sci. 2021 May 3;22(9):4844. doi: 10.3390/ijms22094844. PMID: 34063646; PMCID: PMC8125361.
7. Axel R. The molecular logic of smell. Scientific American. 1995;273(4):154-9. PubMed PMID: 7481719.
8. Felten DL, Shetty AN, editors. Netter's Atlas of Neuroscience. 2 ed. Philadelphia: Saunders; 2010.

METHODS


RESULTS

	Subjects Correctly Identified Aromatherapy				
Overall	22%				
Lavender	33%				
Jojoba	22%				
Orange	29%				
Ginger	0%				

PERCENT SUBJECTS REPORTING REDUCED SYMPTOM SEVERITY BY AROMATHERAPY



AROMATHERAPY HELPED REDUCE SYMPTOMS





STUDY POPULATION

	Lavender (N=23)	Jojoba (N=23)	Orange N=22	Ginger (N=23)	Total (N=91)
o/)	((10 -07			
%)	10 (02 C)		20 (00 0)	10 (02 C)	00 (07 0)
URMC	19 (82.6)	22 (95.7)	20 (90.9)	19 (82.6)	80 (87.9)
RPCI	4 (17.4)	1 (4.4)	2 (9.1)	4 (17.4)	1 (12.1)
Mean (min, max)	46 (13 <i>,</i> 79)	50 (15 <i>,</i> 68)	52 (16, 74)	51 (15, 79)	50 (13, 79)
Median (IQR)	47 (26 <i>,</i> 59)	51 (42 <i>,</i> 61)	56 (43 <i>,</i> 62)	42 (41, 63)	52, (42, 61)
, n (%)					
Male	2 (8.7)	3 (13.0)	3 (13.6)	4 (17.4)	12 (13.2)
Female	21 (91.3)	20 (87.0)	19 (86.4)	19 (82.6)	79 (86.8)
(%)					
White	19 (82.6)	19 (82.6)	20 (90.9)	21 (91.3)	79 (86.8)
Black	3 (13.0)	3 (13.0)	2 (9.1)	2 (8.7)	10 (11.0)
Asian	1 (4.4)	0	0	0	1 (1.1)
Missing	° Ó	1 (4.4)	0	0	1 (1.1)
c Ethnicity, n (%)	2 (8.7)	1 (4.4)	0	2 (8.7)	5 (5.5)
Type, n (%)					
Leukemia	0	0	0	1 (4.4)	1 (1.1)
Hematologic	3 (13.0)	1 (4.4)	2 (9.1)	1 (4.4)	7 (7.7)
Head & Neck	0	0	0	2 (8.7)	2 (2.2)
Lung	0	0	0	2 (8.7)	2 (2.2)
GI	1 (4.4)	5 (21.7)	2 (9.1)	3 (13.0)	11 (12.1)
GU	0	0	0	1 (4.4)	1 (1.1)
Gynecologic	4 (17.4)	5 (21.7)	7 (31.8)	6 (26.1)	22 (24.2)
Breast	14 (60.9)	12 (52.2)	10 (45.5)	7 (30.4)	43 (47.3)
Sarcoma	0	0	1 (4.6)	0	1 (1.1)
Missing	1 (4.4)	0	0	0	1 (1.1)

CONCLUSIONS

• Blinding appeared successful with only 22% of subjects identifying their correct aromatherapy arm.

 Aromatherapy is an acceptable and feasible complementary approach for managing chemotherapy-related symptoms.

• Given the variation in symptom relief across aromatherapy scents, future studies should investigate the effectiveness of aromatherapy blends on overall symptom relief.